Jack Bendheim sold $297k of PAHC
President and CEO at PHIBRO ANIMAL HEALTH CORP. 7,040 shares at an average of $42.16, traded Nov 4, 2025, filed Nov 6, 2025.
Score components
- +25RoleCEO
- +14Trade size$297k at market
- +5Share of holdings soldSold 10% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.8%, 3m +16.5%, 6m +0.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-107913, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 4, 2025 | CConversion Class A Common Stockindirect: See10b5-1 | +25,000 | $0.00 | $0 | 69,440 | Nov 6, 2025 |
| Nov 4, 2025 | SOpen-market sale Class A Common Stockindirect: See10b5-1 | -2,996 | $43.01 | $129k | 66,444 | Nov 6, 2025 |
| Nov 4, 2025 | SOpen-market sale Class A Common Stockindirect: See10b5-1 | -524 | $43.62 | $23k | 65,920 | Nov 6, 2025 |
| Nov 5, 2025 | SOpen-market sale Class A Common Stockindirect: See10b5-1 | -2,548 | $40.98 | $104k | 63,372 | Nov 6, 2025 |
| Nov 5, 2025 | SOpen-market sale Class A Common Stockindirect: See10b5-1 | -972 | $41.83 | $41k | 62,400 | Nov 6, 2025 |
| Nov 4, 2025 | CConversion Class B Common Stockderivativeindirect: See10b5-1 | -25,000 | $0.00 | $0 | 20,061,034 | Nov 6, 2025 |
Related signals
Other insiders at PHIBRO ANIMAL HEALTH CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | PAHCbuy PHIBRO ANIMAL HEALTH CORP | E Thomas Corcoran director | $318k 10,000 shares | +32% | |
| 35Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.0M 18,608 shares | -25% | |
| 35Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.1M 21,120 shares | -22% | |
| 35Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.2M 21,120 shares | -18% | |
| 50Moderate | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.2M 21,120 shares | -55% | |
| 37Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $757k 14,080 shares | -27% | |
| 40Moderate | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.2M 21,120 shares | -29% | |
| 35Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.2M 22,880 shares | -24% | |
| 18Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $258k 5,280 shares | -5% | |
| 50Moderate | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.1M 21,120 shares | -93% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.